{
    "clinical_study": {
        "@rank": "74", 
        "arm_group": {
            "arm_group_label": "EPO906", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will examine whether the new investigational drug EPO906, given by intravenous\n      infusion (IV directly into the vein), is effective in shrinking tumors and preventing the\n      growth of cells that cause ovarian, fallopian, or peritoneal cancers.  Recruitment in the\n      United States is complete but the study is still enrolling in other countries."
        }, 
        "brief_title": "EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer", 
        "condition": [
            "Ovarian Neoplasms", 
            "Peritoneal Neoplasms", 
            "Fallopian Tube Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Fallopian Tube Neoplasms", 
                "Ovarian Neoplasms", 
                "Peritoneal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        The following patients may be eligible for the study:\n\n          -  Histologically or cytologically documented evidence of ovarian, primary Fallopian or\n             primary peritoneal cancer with at least one measurable lesion (if previous radiation\n             treatment, the target lesion must have demonstrated progression since the radiation)\n\n          -  Must have a life expectancy of greater than three (3) months\n\n          -  Prior failure to respond following front-line treatment with a taxane and platinum\n             (or a combination therapy) may be eligible.\n\n        Exclusion Criteria:\n\n        The following patients are not eligible for the study:\n\n          -  Patients with radiation therapy or chemotherapy within the last four weeks\n\n          -  Patients who have had any chemotherapy not containing a taxane and platinum for their\n             disease\n\n          -  Patients with borderline ovarian and macropapillary tumors\n\n          -  Patients with unresolved bowel obstruction\n\n          -  Patients with symptomatic CNS metastases or leptomeningeal involvement\n\n          -  Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1\n\n          -  Patients with severe cardiac insufficiency\n\n          -  Patients taking Coumadin or other warfarin-containing agents with the exception of\n             low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports\n\n          -  History of another malignancy within 5 years prior to study entry except curatively\n             treated non-melanoma skin cancer or cervical cancer in situ\n\n          -  Patients with active or suspected acute or chronic uncontrolled infection including\n             abcesses or fistulae\n\n          -  HIV+ patients\n\n          -  Pregnant or lactating females."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00035100", 
            "org_study_id": "CEPO906A2203"
        }, 
        "intervention": {
            "arm_group_label": "EPO906", 
            "intervention_name": "epothilone b", 
            "intervention_type": "Drug", 
            "other_name": "EPO906"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Epothilone B", 
                "Epothilones"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "ovarian", 
            "ovary", 
            "peritoneal cancer", 
            "fallopian cancer", 
            "cancer", 
            "tumor", 
            "tumour", 
            "neoplasm", 
            "carcinoma", 
            "intravenous", 
            "epothilone"
        ], 
        "lastchanged_date": "April 13, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Brunswick", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08901"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1066 CX"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Enschede", 
                        "country": "Netherlands", 
                        "zip": "7513 ER"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zwolle", 
                        "country": "Netherlands", 
                        "zip": "8025 AB"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bratislava", 
                        "country": "Slovakia", 
                        "zip": "812 50"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kosice", 
                        "country": "Slovakia", 
                        "zip": "04190"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Surrey", 
                        "country": "United Kingdom", 
                        "zip": "SM2 5PT"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Netherlands", 
                "Slovakia", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "tumor response was defined by the Response Evaluation Criteria in Solid Tumors (RECIST).", 
            "measure": "Tumor response rate", 
            "safety_issue": "No", 
            "time_frame": "Every 2 cycles"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035100"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to disease progression", 
                "safety_issue": "No", 
                "time_frame": "from start of treatment to documented disease progression, death from study indication, or the date of last follow-up"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "measured from the start of treatment to the date of death or the last date the patient was known to be alive."
            }, 
            {
                "description": "duration of response in patients with complete response (CR) or partial response (PR)", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months"
            }, 
            {
                "description": "Safety and tolerability of patupilone by monitoring and recording all AEs and SAEs, regular monitoring of hematology, blood chemistry  and urine lalues, vital signs, ECG and physical examinations", 
                "measure": "recording all adverse events (AEs) and serious adverse events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Every 3 months"
            }, 
            {
                "measure": "pharmacogenetic analyses with blood and tumor samples from these patients", 
                "safety_issue": "Yes", 
                "time_frame": "Every 3 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2012"
    }, 
    "geocoordinates": {
        "Novartis Investigative Site": "51.262 -0.467"
    }
}